[Oral iron and folic acid supplements in a preoperative autologous blood collection program: a randomized study]. / Suplementos de hierro oral y ácido fólico en un programa de transfusión autóloga con predepósito: estudio aleatorizado.

BACKGROUND AND OBJECTIVE: We evaluated the capacity of oral iron with or without oral folic acid administration to improve the accomplishment of our scheduled preoperative autologous blood collection program in patients with baseline hemoglobin > 115 g/l. PATIENTS AND METHOD: Patients were enrolled in a randomized trial. The control group received no vitamin supplements. The iron group received 105 mg of elemental iron daily p.o. The and iron+folate group received 105 mg of elemental iron daily and 5 mg of folic acid daily p.o. RESULTS: Eighty-six percent of patients in the control group, 86% of patients in the iron group and 87% of patients in the iron+folate group accomplished our preoperative autologous blood collection program. CONCLUSION: In our study, neither oral iron nor folic acid supplements enhanced the accomplishment of our preoperative autologous blood collection program in patients with baseline hemoglobin > 115 g/l.

Suplementos de hierro oral y ácido fólico en un programa de transfusión autóloga con predepósito: estudio aleatorizado / Oral iron and folic acid supplements in a preoperative autologous blood collection program: a randomized study

FUNDAMENTO Y OBJETIVO: Evaluar la capacidad del hierro oral con administración de ácido fólico oral o sin ella para mejorar el cumplimiento de un programa de recogida de sangre autóloga con predepósito (PRSAP) en pacientes con cifras basales de hemoglobina superior a 115 g/l. PACIENTES Y MÉTODO: Los pacientes incluidos en el estudio fueron aleatorizados en 3 grupos: el grupo control no recibió suplementos vitamínicos; el grupo con hierro recibió105 mg de hierro elemental diario por vía oral y el grupo hierro + fólico recibió 105mg de hierro elemental diario y 5 mg de ácido fólico diario por vía oral. RESULTADOS: El 86% de los pacientes del grupo control, el 86% del grupo con hierro y el 87% del grupo hierro + fólico consiguieron cumplir nuestro PRSAP.CONCLUSIÓN: En nuestro estudio, los suplementos de hierro oral, con o sin ácido fólico oral, no mejoran el cumplimiento de nuestro PRSAP en pacientes con cifras basales de hemoglobina superiores a 115 g/l

BACKGROUND AND OBJECTIVE: We evaluated the capacity of oral iron with or without oral folicacid administration to improve the accomplishment of our scheduled preoperative autologous blood collection program in patients with base line hemoglobin > 115g/l. PATIENTS AND METHOD: Patients were enrolled in a randomized trial. The control group received no vitamin supplements. The iron group received 105 mg of elemental irondaily p.o. The and iron+folate group received105 mg of elemental iron daily and 5 mg of folic acid daily p.o. RESULTS: Eighty-six percent of patients in the control group, 86% of patients in the iron group and 87% of patients in the iron+ folate group accomplished our preoperativeautologous blood collection program. CONCLUSION: In our study, neither oral iron or folic acid supplements enhanced the accomplishment of our preoperative autologous blood collection program in patients with baseline hemoglobin > 115 g/l

Use of polyethylene glycol for performing autologous adsorptions.

BACKGROUND: Our reference adsorption procedure is to autoadsorb serum with ZZAP-pretreated patients' red cells (RBCs), although it is time-consuming. The aim of this study was to evaluate the use of polyethylene glycol (PEG) for performing autologous adsorption procedures without pretreatment of patients' RBCs. STUDY DESIGN AND METHODS: Equal volumes of patient's plasma, patient's RBCs, and PEG were mixed. This mixture was incubated for 15 minutes at 37 degrees C, and the adsorbed plasma-PEG mixture was immediately harvested to proceed to the antiglobulin test with anti-immunoglobulin G. The ZZAP-adsorption procedure was performed in our reference laboratory. RESULTS: Thirty-one samples were detected with warm autoantibodies in pretransfusion testing. A total number of 58 autologous adsorption procedures were performed with PEG in 870 minutes (mean, 28 min) and alloantibodies were detected in 4 (13%) cases (anti-E in 2 cases and anti-E + K in 2 cases). Our reference laboratory performed a total number of 61 adsorption procedures with ZZAP in 3660 minutes (mean, 118 min) and detected the same alloantibodies specificities. CONCLUSION: The PEG autologous adsorption procedure is an efficient method of enhancing autoantibody adsorption and alloantibody detection and decreasing the labor-intensive testing required by the presence of serum warm autoantibodies in pretransfusion samples.

Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions.

BACKGROUND: Rh antigens are not present on the platelet surface. However, platelet concentrates may contain enough RBCs to elicit an anti-D response. Thus, D status must be considered in platelet transfusion. In immunosuppressed patients, frequencies of D alloimmunization of up to 19 percent have been previously reported. STUDY DESIGN AND METHODS: Here a prospective study is reported in which 22 D- patients with hematologic disease received D+ platelet transfusions. Platelet concentrates were prepared from whole-blood donations according to the buffy coat method and were pooled before administration. The antibody screen test to detect anti-D was performed by LISS- IAT using the gel test. RESULTS: Our series comprises 22 immunosuppressed D+ patients with a median age of 56 years (range, 23-79). The patients received 121 D-incompatible pooled platelet transfusions. The mean +/- SD of RBC content was 4.17 +/- 1.74 mL. None of the 22 patients developed detectable anti-D after a median follow-up of 8 weeks (range, 1-37). CONCLUSION: The risk of D alloimmunization is low in patients with hematologic disease after D-incompatible platelet transfusions using platelet concentrates prepared by the buffy coat method.